Mark Cuban Cost Plus Drugs partners with Scripta Insights to bring transparent drug pricing to patients. Scripta’s platform, Med Mapper, integrates Cost Plus Drugs’ discounted pricing, offering personalized savings reports for medication options. The collaboration aims to empower patients with informed choices and lower prescription drug costs. Cost Plus Drugs previously tapped RevSpring for healthcare payment technology and entered the male fertility space through a partnership with Posterity Health. The alliance seeks to revolutionize the pharmacy industry by providing fair prices and convenient access to medications.
Mark Cuban Cost Plus Drugs has announced a strategic partnership with Scripta Insights, a leading pharmacy navigation startup in the digital health industry. The collaboration aims to revolutionize drug pricing transparency for patients.
Under this partnership, Scripta Insights will integrate Cost Plus Drugs’ discounted pricing into its platform, Med Mapper. Med Mapper is a comprehensive tool that maps all available drugs on the market and provides users with various ways to save money on their medications. By using Scripta’s member app and portal, patients can access personalized savings reports, which present alternative prescription options covered by their health plans or cash-pay options like those offered by Cost Plus Drugs.
Eric Levin, CEO of Scripta Insights, expressed enthusiasm about the collaboration, emphasizing Mark Cuban’s entrepreneurial spirit aligning with their mission to empower patients with informed choices in the pharmacy benefit market. He lauded Cost Plus Drugs for its unprecedented deep discounts, transparent pricing, and vertically-integrated supply chain.
Founded in 2019, Scripta Insights serves self-insured employers, health plans, and their members. Its proprietary AI platform, Med Mapper, was developed with the expertise of doctors, pharmacists, and data analysts. The company’s goal is to provide user-friendly tools to human resource and pharmacy teams, enabling members to understand their medication options better, adhere to provider instructions, and achieve improved health outcomes. These tools also aim to lower out-of-pocket costs and overall plan spending for patients.
Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, expressed excitement about collaborating with Scripta Insights to offer consumers lower prescription drug prices. Both companies share a common objective of providing consumers with the lowest possible price for their prescription medications. Cost Plus Drugs’ commitment to transparent pricing and the convenience of delivering medications directly to consumers’ homes aligns with Scripta’s mission.
Notably, Cost Plus Drugs recently partnered with RevSpring, a healthcare payment solutions provider, to implement advanced payment technology for its program with U.S. pharmacies. This program seeks to make drugs more affordable and alleviate financial stress for participating pharmacies by increasing their revenue.
Additionally, Cost Plus Drugs expanded its services to address male fertility issues by teaming up with Posterity Health. This collaboration aims to improve access to affordable medications that treat infertility, low testosterone, and sexual dysfunction for men.
The partnership between Mark Cuban Cost Plus Drugs and Scripta Insights holds the promise of revolutionizing the pharmacy industry by empowering patients with transparent drug pricing and cost-saving options, ultimately enhancing healthcare outcomes and affordability for consumers.
